8th Oct 2007 07:01
Skyepharma PLC08 October 2007 For Immediate Release 8 October 2007 Solaraze -Change of Marketing Partner LONDON, UK - 8 October 2007 -- SkyePharma PLC (LSE: SKP) announces that thedistribution and marketing rights for Solaraze(R) are being divested by Shireplc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) to Almirall together with a portfolio ofother products which are principally sold by Shire in the UK, France, Germany,Italy, Spain and Ireland. Solaraze(R) (diclofenac), is a topical preparation for the treatment of actinickeratoses, which are common skin lesions on areas damaged extensively bysunlight. It is marketed in the US by Doak Dermatologics, a subsidiary ofBradley Pharmaceuticals Inc. and has recently been launched in Australia by CSLBiotherapies under an agreement with Shire. SkyePharma receives a low teensroyalty on relevant net sales; this is not affected by the proposed transferfrom Shire to Almirall. The transfer from Shire to Almirall is contingent on competition clearances andother customary consents. Frank Condella, CEO of SkyePharma PLC said: "Almirall is well positioned toensure future development and investment in Solaraze(R) and we expect it to getthe focus it needs to continue to grow in all its key markets." For further information please contact:SkyePharma PLCFrank Condella, Chief Executive OfficerKen Cunningham, Chief Operating Officer +44 207 491 1777Peter Grant, Finance Director Financial Dynamics (London enquiries)David Yates / Deborah Scott +44 207 831 3113 Trout Group (US enquiries)Christine Labaree / Seth Lewis +1 617 583 1308 About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops newformulations of known molecules to provide a clinical advantage and life-cycleextension. The Company has eleven approved products in the areas of oral,inhalation and topical delivery. The Group's products are marketed throughoutthe world by leading pharmaceutical companies. For more information, visitwww.skyepharma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.LShire